News | May 09, 2012

3-D Imaging in the OR Aims to Revolutionize Radio-Guided Surgeries

May 9, 2012 — For decades, non-imaging gamma probes have been used to guide surgeons to critical lymph nodes in cancer patients. More recently, a procedure has been developed to guide tumor surgery using the same probe; however the non-imaging probes used in these procedures cannot provide accurate depth information. According to results presented by two medical institutions at the Society of Surgical Oncology 2012 Annual Cancer Symposium on March 21, the SurgicEye declipseSPECT (single photon emission computed tomography), an intra-operative handheld 3-D image-viewing device cleared by the U.S. Food and Drug Administration (FDA), may improve the accuracy of these procedures by providing 3-D images of the tumor and lymph nodes.

Leading surgeons from the Netherlands Cancer Institute in Amsterdam presented on the use of the declipseSPECT in the radio-guided resection of non-palpable breast cancer. Their results showed that declipseSPECT could support radio-guided surgery by determining the precise 3-D localization of the marked cancer and lymph nodes in the operating room. In addition, the system allowed them to determine the depth of each structure and to image the lumpectomy specimen to verify margins; all margins were verified to be negative by pathology.

“The innovative 3-D declipseSPECT technology may make the sentinel node biopsy easier and more reliable. New technologies like 3-D declipseSPECT will also open up lymphatic mapping to additional cancer types, cancer types in locations with a more intricate anatomy and cancer types with more complex lymph drainage," said lead author, Omgo E. Nieweg, the Netherlands Cancer Institute.

The team of surgeons from the general surgery department of the University Hospital of the Technische Universitat Munchen, Munich, Germany, presented on the use of the declipseSPECT in locating sentinel nodes of melanoma patients. The system enabled the physicians to intra-operatively image all of the nodes seen in pre-operative imaging. In addition, by using the device for post-excision imaging in the operating room, the team was able to confirm and document complete resection of the nodes.

The declipseSPECT device is provided in the United States exclusively by Dilon Diagnostics. “The declipseSPECT system is a natural fit for our product portfolio since it extends gamma imaging capabilities in the operating room. We are excited and encouraged by these results and our company continues to lead the molecular imaging market through innovation and partnerships like the one we share with SurgicEye,” said Dilon CEO Robert Moussa.

For more information: www.molecularbreastimaging.com, www.surgiceye.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
X-ray performed on a GE Optima 646 DR system. The FDA has updated its radiology reporting forms on its website.
News | Business | July 24, 2017
July 24, 2017 — The U.S.
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init